The … http://www.akebia.com. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. Akebia Therapeutics, Inc. has 324 employees and is ranked 5th among it's top 10 competitors. Verify Akebia Therapeutics Inc employees. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Let Truework help you complete employment and income verifications faster. Together they have raised over 1.1B between their estimated 19.5K employees. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. The total cash compensation, which includes bonus, and annual incentives, can vary anywhere from $197,890 to $285,190 with the average total cash compensation of $235,990. This is the Akebia Therapeutics company profile. Akebia Therapeutics, Inc. is a biopharmaceutical company. Please check your download folder. The total cash compensation, which includes bonus, and annual incentives, can vary anywhere from $197,890 to $285,190 with the average total cash compensation of $235,990. Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. E mpl oye r I de nti fi c ati on No.) Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF), Akebia Therapeutics Number of Employees 2013-2020 | AKBA. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Business Description. Akebia Therapeutics Inc is a biopharmaceutical company. The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Akebia Therapeutics is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all … We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. The process is simple, automated, and most employees are verified within 24 hours. 245 First Street Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Cambridge, MA 02142 +1 617.871.2098 phone +1 617.871.2099 fax. The base salary for Global Employee Benefits Executive in companies like AKEBIA THERAPEUTICS INC range from $170,390 to $225,490 with the average base salary of $194,390. Nektar Therapeutics number of employees from 2006 to 2020. E mpl oye r I de nti fi c ati on No.) By continuing to use this website you agree to our use of cookies. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Verify Akebia Therapeutics Inc employees. The Company's lead product candidate, vadadustat, is indicated for the … READ OUR COMPANY STATEMENT (8.10.20) For patients in the U.S. taking a prescribed Akebia product, please visit AkebiaCares.com or call 855-686-8601 for assistance. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Akebia Therapeutics Inc is a biopharmaceutical company. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails We use cookies in order to provide you with a better browsing experience . Akebia Therapeutics Inc. is a biopharmaceutical company. “Participant”: An Eligible Employee who elects to enroll in the Plan. Apply to Director, Associate Director, Director of Accounting and more! Suite 1100 Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails We use cookies in order to provide you with a better browsing experience . All content is posted anonymously by employees working at Akebia Therapeutics. Akebia Therapeutics currently has 12 job openings. OF EMPLOYEES. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The base salary for Global Employee Benefits Executive in companies like AKEBIA THERAPEUTICS INC range from $170,390 to $225,490 with the average base salary of $194,390. Akebia Therapeutics serves customers in the United States. Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney … Akebia Therapeutics, Inc.'s top 17 competitors are Athersys, Ricerca, Aerpio, Organogenesis, Tengion, ONL Therapeutics, Covance, Celerion, Rmks. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. 35 Akebia Therapeutics $50,000 jobs available on Indeed.com. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “Plan”: The Akebia Therapeutics, Inc. 2014 Employee Stock Purchase Plan, as from time to time amended and in effect. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Akebia Therapeutics grew their employee count by 16% last year. Akebia Therapeutics, Inc. is a biopharmaceutical company. Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts and a Global leader in hypoxia inducible factor (HIF) Biology, focused on delivering innovative therapies to patients with kidney disease and pursuing advances across … Akebia needs to continue support the employees on work life balance especially in this new virtual world. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. Akebia Therapeutics Annual Number of Employees; 2019: 360: 2018: 325: 2017: 114: 2016: 90: 2015: 64: 2014: 43: 2013: 28: 2012 Akebia Therapeutics, Inc.'s top 17 competitors are Athersys, Ricerca, Aerpio, Organogenesis, Tengion, ONL Therapeutics, Covance, Celerion, Rmks. By continuing to use this website you agree to … The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. Together they have raised over 1.1B between their estimated 19.5K employees. A free inside look at company reviews and salaries posted anonymously by employees. “Purchase Price”: The price per share of Stock with respect to an Option Period determined in … The process is simple, automated, and most employees are verified within 24 hours. Glassdoor gives you an inside look at what it's like to work at Akebia Therapeutics, including salaries, reviews, office photos, and more. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics started at outperform with $18 stock price target at Raymond James Aug. 14, 2018 at 8:27 a.m. As a member of the renal community, the health of our patients and employees is our first priority. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis In depth view into Akebia Therapeutics Total Employees (Annual) including historical data from 2014, charts, stats and industry comps. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Back to AKBA Overview ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. 32 Akebia Therapeutics reviews. Company profile page for Akebia Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information. Sector(s): Healthcare Industry: Biotechnology Full Time Employees: 358 Akebia Therapeutics, Inc. manufactures biopharmaceutical products. Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each such employee's entering into employment with Akebia. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. 360. Employee Data Akebia Therapeutics has 398 Employees. For all general inquiries, please contact: Akebia Therapeutics, Inc. has 324 employees and is ranked 5th among it's top 10 competitors. ... NO. Akebia Therapeutics number of employees from 2013 to 2020. Akebia Therapeutics 2020-11-06 07:26 PST See All 41 Reviews Please check your download folder. United States, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics, Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates, Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights, Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidne, Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadusta, Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates, Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined. Akebia Therapeutics General Information Description. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript detailing the study design and methodology for its global Phase 3 INNO2VATE program in Nephrology Dialysis Transplantation (NDT), the official journal for the European Renal Association … A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to … Akebia Therapeutics, Inc. 245 First Street, Suite 1400. Akebia Therapeutics number of employees from 2013 to 2020. Akebia Therapeutics, Inc. Common Stock (AKBA) Revenue EPS : Previous 3 Years Next 3 Years. AKEBIA THERAPEUTICS, INC. (E xac t name of re gi s tr ant as s pe c i fi e d i n i ts c har te r ) Delaware 20-8756903 (State or othe r jur i s di c ti on of i nc or por ati on or or gani z ati on) (I .R.S. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. Akebia Therapeutics Biotechnology Cambridge, MA 19,529 followers We're focused on the development & commercialization of therapeutics for people living with kidney disease. Cambridge, MA 02142 The Company's lead product candidate, vadadustat, is indicated for the … 245 First Street , Cambridge, MA 02142 AKEBIA THERAPEUTICS, INC. (E xac t name of re gi s tr ant as s pe c i fi e d i n i ts c har te r ) Delaware 20-8756903 (State or othe r jur i s di c ti on of i nc or por ati on or or gani z ati on) (I .R.S. Let Truework help you complete employment and income verifications faster. 245 First Street , Cambridge, MA 02142